Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL

evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Mingzhi ZhangUpdated: Jul 14, 2025Locations: 1
Eligibility criteria

Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70); [+9]

Refuse to collect blood samples; [+12]

Status: Recruiting

A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma

Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Mingzhi ZhangUpdated: Nov 12, 2024Locations: 1
Eligibility criteria

Individuals aged 65 years or older who are intolerant to chemotherapy, regardles... [+12]

Clear patients with neurological or psychiatric disorders, including dementia or... [+15]

Status: Not yet recruiting

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrent/refractory malignant hematological lymphomas

Participants needed: 30
Trial details
Phase: Phase 1Age: 14-75Biological sex: AllType: InterventionalSponsor: Mingzhi ZhangUpdated: Oct 17, 2024Locations: 1
Eligibility criteria

The participant has given informed consent and signed the consent form, and is w... [+8]

History of any of the following cardiovascular diseases within the past 6 months... [+14]